ALKS Alkermes plc Stock Quote

ALKS [NASD]

Index	-	P/E	-	EPS (ttm)	-0.47	Insider Own	0.10%	Shs Outstand	159.06M	Perf Week	0.86%
Market Cap	3.42B	Forward P/E	44.38	EPS next Y	0.50	Insider Trans	-19.47%	Shs Float	157.63M	Perf Month	1.79%
Income	-73.60M	PEG	-	EPS next Q	0.07	Inst Own	-	Short Float	7.30%	Perf Quarter	36.47%
Sales	1.17B	P/S	2.92	EPS this Y	-39.40%	Inst Trans	0.00%	Short Ratio	9.06	Perf Half Y	10.51%
Book/sh	6.82	P/B	3.25	EPS next Y	27.23%	ROA	-4.00%	Target Price	21.36	Perf Year	19.43%
Cash/sh	3.70	P/C	6.00	EPS next 5Y	-14.10%	ROE	-6.90%	52W Range	11.98 - 23.02	Perf YTD	11.23%
Dividend	-	P/FCF	-	EPS past 5Y	-43.30%	ROI	-12.80%	52W High	-3.61%	Beta	0.97
Dividend %	-	Quick Ratio	2.40	Sales past 5Y	13.60%	Gross Margin	84.50%	52W Low	85.23%	ATR	0.89
Employees	2235	Current Ratio	2.70	Sales Q/Q	3.80%	Oper. Margin	-7.80%	RSI (14)	59.31	Volatility	4.59% 4.30%
Optionable	Yes	Debt/Eq	0.25	EPS Q/Q	99.80%	Profit Margin	-6.30%	Rel Volume	1.40	Prev Close	21.47
Shortable	Yes	LT Debt/Eq	0.25	Earnings	Oct 29 BMO	Payout	-	Avg Volume	1.27M	Price	22.19
Recom	3.00	SMA20	5.00%	SMA50	11.19%	SMA200	24.23%	Volume	1,784,488	Change	3.35%

Oct-15-20

Upgrade

Mizuho

Neutral → Buy

$19 → $24

Jul-30-20

Downgrade

Goldman

Neutral → Sell

$19 → $15

Feb-14-20

Reiterated

H.C. Wainwright

Neutral

$26 → $25

Feb-14-20

Downgrade

JP Morgan

Overweight → Neutral

$21

Feb-14-20

Downgrade

BofA/Merrill

Buy → Neutral

$31 → $20

Feb-06-20

Initiated

Mizuho

Neutral

Jan-31-20

Upgrade

Wolfe Research

Underperform → Peer Perform

Sep-05-19

Upgrade

Morgan Stanley

Underweight → Equal-Weight

$30 → $20

Jul-15-19

Upgrade

Goldman

Sell → Neutral

May-31-19

Initiated

H.C. Wainwright

Neutral

May-01-19

Downgrade

Citigroup

Buy → Neutral

Dec-19-18

Downgrade

Goldman

Neutral → Sell

Dec-14-18

Initiated

Wolfe Research

Underperform

Dec-13-18

Downgrade

Credit Suisse

Outperform → Underperform

Nov-05-18

Initiated

Piper Jaffray

Neutral

$40

Aug-07-18

Initiated

Stifel

Hold

$15 → $45

Jun-21-18

Downgrade

Morgan Stanley

Equal-Weight → Underweight

Jun-06-18

Initiated

B. Riley FBR, Inc.

Buy

$60

May-16-18

Upgrade

Citigroup

Neutral → Buy

May-11-18

Initiated

BofA/Merrill

Buy

$56

Jan-22-21 09:02AM	Ultragenyx's (RARE) IND for Wilson Disease Cleared by FDA Zacks
Jan-21-21 12:57PM	Bristol Myers' (BMY) Opdivo Label Expansion Gets Priority Review Zacks
12:16PM	Novo Nordisk (NVO) Files for Ozempic's Label Expansion in US Zacks
07:14AM	AstraZeneca's (AZN) Enhertu Gets EU Nod for Breast Cancer Zacks
Jan-15-21 09:11AM	Novartis' (NVS) Ligelizumab Gets Breakthrough Therapy Status Zacks
Jan-14-21 10:46AM	Marinus (MRNS) Gets Positive FDA Response for Ganaxolone Study Zacks
07:00AM	NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine PR Newswire
Jan-13-21 02:17PM	Regeneron (REGN), U.S. Government Ink Deal for COVID-19 Treatment Zacks
Jan-12-21 10:27AM	Horizon (HZNP) Provides Preliminary 2020 Financial Results Zacks
10:04AM	Ultragenyx (RARE) Presents Preliminary 2020 Revenues & Guidance Zacks
Jan-11-21 08:46AM	NuCana (NCNA) Looks Good: Stock Adds 5.7% in Session Zacks +5.30%
Jan-08-21 09:57AM	Alnylam (ALNY) Posts Positive Top-Line Data From Vutrisiran Study Zacks
Jan-07-21 10:52AM	Catayst (CPRX) Provides Long-Term Portfolio Expansion Plans Zacks +5.56%
10:51AM	Infinity (INFI) Provides Data on Eganelisib in Urothelial Cancer Zacks
08:45AM	AbbVie Is Mizuhos Top Pick Among Large-Cap Biopharma Stocks Barrons.com
Jan-06-21 04:00PM	Alkermes to Present at the 39th Annual J.P. Morgan Healthcare Conference PR Newswire
11:13AM	REGENXBIO (RGNX) Provides Update on RGX-314 & Begins New Program Zacks
09:24AM	Aerpio (ARPO) Seeks Strategic Options for Pipeline Programs Zacks
07:00AM	Alkermes Announces Updates to Executive Leadership Team PR Newswire
Dec-29-20 10:23AM	FDA Accepts Alkermes' New Drug Application Resubmission TheStreet.com
08:09AM	The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica Benzinga
07:00AM	FDA Accepts Alkermes' Resubmission of New Drug Application for ALKS 3831 PR Newswire
Dec-28-20 10:00AM	Apellis' (APLS) Pipeline Candidate Pegcetacoplan Promising Zacks
Dec-24-20 11:25PM	Alkermes plc's (NASDAQ:ALKS) Shift From Loss To Profit Simply Wall St.
09:14AM	Bristol Myers' (BMY) CNS Phase III Cancer Study on Opdivo Fails Zacks
Dec-22-20 12:00PM	Alkermes (ALKS) Moves to Buy: Rationale Behind the Upgrade Zacks
Dec-11-20 08:34AM	Alkermes (ALKS) Outlines Value Enhancement Plan, Shares Up Zacks
Dec-10-20 02:58PM	Here's Why Alkermes Shares Jumped Higher Today Motley Fool +12.70%
07:00AM	Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment PR Newswire
Nov-23-20 11:35PM	What Did Alkermes' (NASDAQ:ALKS) CEO Take Home Last Year? Simply Wall St.
Nov-18-20 12:24PM	Biotech Stock Roundup: MRNA's Progress With Coronavirus Vaccine, News From BMY, ALKS Zacks
11:13AM	Alkermes (ALKS) Receives FDA CRL in Relation to ALKS 3831 Zacks
10:49AM	Alkermes, Inc. -- Moody's affirms Alkermes at Ba3; stable outlook Moody's
Nov-17-20 08:31AM	The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration Benzinga
07:00AM	Alkermes Receives FDA Complete Response Letter Related to ALKS 3831 Manufacturing Records Review PR Newswire
Nov-09-20 08:01AM	Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting PR Newswire +5.35%
Nov-03-20 04:00PM	Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates Benzinga
Oct-30-20 06:00PM	Alkermes PLC (ALKS) Q3 2020 Earnings Call Transcript Motley Fool
03:54PM	Alkermes (ALKS) Beats on Q3 Earnings & Sales, Lifts Guidance Zacks
Oct-29-20 10:24AM	Alkermes Reschedules Third Quarter 2020 Financial Results Conference Call to 10:30 a.m. ET PR Newswire +5.78%
08:45AM	Alkermes (ALKS) Tops Q3 Earnings and Revenue Estimates Zacks
07:00AM	Alkermes plc Reports Third Quarter 2020 Financial Results and Raises 2020 Financial Expectations PR Newswire
06:00AM	Alkermes Plc to Host Earnings Call ACCESSWIRE
Oct-27-20 10:38AM	Horizon (HZNP) to Report Q3 Earnings: What's in the Cards? Zacks
10:31AM	Bayer (BAYRY) to Report Q3 Earnings: What's in the Cards? Zacks
Oct-26-20 09:22AM	Trevena (TRVN) to Report Q3 Earnings: What's in the Cards? Zacks
Oct-22-20 04:00PM	Alkermes to Host Conference Call to Discuss Third Quarter 2020 Financial Results PR Newswire
11:19AM	Alexion (ALXN) to Report Q3 Earnings: What's in the Cards? Zacks
Oct-21-20 12:33PM	Alkermes (ALKS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Zacks
Oct-19-20 06:59AM	Is Alkermes (NASDAQ:ALKS) Using Debt Sensibly? Simply Wall St.
Oct-12-20 04:12PM	Alkermes Nears FDA Ruling For Its Bipolar Treatment With Key Endorsement; ALKS Stock Jumps Investor's Business Daily
10:35AM	Alkermes' Schizophrenia Drug Gets Favorable FDA Panel Vote Zacks
Oct-09-20 05:11PM	FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I Disorder PR Newswire
07:05AM	Trading in Alkermes Ordinary Shares Halted Today PR Newswire
Oct-07-20 10:14AM	Alkermes Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on ALKS 3831 PR Newswire +6.01%
Sep-28-20 08:53PM	Alkermes Plc (ALKS): Hedge Funds Taking Some Chips Off The Table Insider Monkey
Sep-25-20 11:40AM	LGND or ALKS: Which Is the Better Value Stock Right Now? Zacks
Sep-18-20 06:30AM	Alkermes Presents New Clinical Data on ALKS 4230 in Mini Oral Presentation at 2020 European Society for Medical Oncology (ESMO) Virtual Congress PR Newswire
Sep-14-20 12:06PM	20 Most Drug Infested Cities in the U.S. Insider Monkey
07:00AM	Alkermes Presents New Psychiatry Data at Psych Congress 2020 Virtual Experience PR Newswire
Sep-13-20 08:59AM	What Type Of Returns Would Alkermes'(NASDAQ:ALKS) Shareholders Have Earned If They Purchased Their SharesFive Years Ago? Simply Wall St.
Sep-09-20 04:00PM	Alkermes to Take Part in Cantor Virtual Global Healthcare Conference PR Newswire
11:40AM	LGND or ALKS: Which Is the Better Value Stock Right Now? Zacks
Sep-08-20 07:00AM	Alkermes to Present New Data on Investigational Immuno-Oncology Candidate, ALKS 4230, at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress PR Newswire
Aug-28-20 11:31AM	Why Is Alkermes (ALKS) Down 12% Since Last Earnings Report? Zacks
Aug-21-20 11:40AM	ANIK vs. ALKS: Which Stock Should Value Investors Buy Now? Zacks -5.64%
07:00AM	Virtual FDA Advisory Committee Meeting to Review New Drug Application for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder Tentatively Scheduled for Oct. 9, 2020 PR Newswire
Aug-20-20 09:42AM	Alkermes Starts Phase II Study on ALKS 4230 for Solid Tumors Zacks
Aug-19-20 07:00AM	Alkermes Initiates Phase 2 Study Designed to Evaluate Clinical and Immunologic Activity of ALKS 4230 on Tumor Microenvironment in Patients with Advanced Solid Tumors PR Newswire
Aug-17-20 07:00AM	American Journal of Psychiatry Publishes Data From Alkermes' Phase 3 ENLIGHTEN-2 Weight Study of ALKS 3831 in Patients With Schizophrenia PR Newswire
Aug-05-20 11:40AM	ANIK or ALKS: Which Is the Better Value Stock Right Now? Zacks
Jul-30-20 07:32PM	10 Biggest Biotechnology Companies Investopedia
11:08AM	Alkermes' (ALKS) Q2 Earnings & Revenues Surpass Estimates Zacks
08:08AM	Estimating The Intrinsic Value Of Alkermes plc (NASDAQ:ALKS) Simply Wall St.
Jul-29-20 05:30PM	Alkermes PLC (ALKS) Q2 2020 Earnings Call Transcript Motley Fool -6.29%
08:45AM	Alkermes (ALKS) Beats Q2 Earnings and Revenue Estimates Zacks
07:40AM	Alkermes: Q2 Earnings Insights Benzinga
Jul-28-20 08:41AM	Why Alkermes (ALKS) Might Surprise This Earnings Season Zacks
Jul-22-20 04:00PM	Alkermes to Host Conference Call to Discuss Second Quarter 2020 Financial Results PR Newswire
Jul-16-20 12:32PM	Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Jul-13-20 10:32AM	Did Hedge Funds Make The Right Call On Alkermes Plc (ALKS) ? Insider Monkey
Jun-30-20 09:36AM	Do Options Traders Know Something About Alkermes (ALKS) Stock We Don't? Zacks
Jun-29-20 07:00AM	Alkermes Announces Launch of 3rd Annual Alkermes Pathways Research Awards® Program PR Newswire
Jun-24-20 07:00AM	Alkermes Awards COVID-19 Relief Fund Grants to 10 Innovative Programs Designed to Address Challenges for Patient Communities PR Newswire
Jun-22-20 09:01AM	New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II PR Newswire
Jun-19-20 06:04PM	Alzheimer's Drug Approval More Critical for Biogen After Patent Decision GuruFocus.com
Jun-16-20 07:28AM	Edited Transcript of ALKS earnings conference call or presentation 29-Apr-20 12:00pm GMT Thomson Reuters StreetEvents +5.27%
Jun-12-20 09:11AM	Should You Avoid Alkermes Plc (ALKS)? Insider Monkey
Jun-08-20 09:04AM	How Alkermes (ALKS) Stock Stands Out in a Strong Industry Zacks
Jun-04-20 04:00PM	Alkermes to Take Part in 41st Annual Goldman Sachs Global Healthcare Conference PR Newswire
May-29-20 11:31AM	Alkermes (ALKS) Up 21.6% Since Last Earnings Report: Can It Continue? Zacks
May-27-20 07:00AM	Alkermes Highlights New Data From Schizophrenia Portfolio at the American Society of Clinical Psychopharmacology 2020 Annual Meeting PR Newswire
May-20-20 07:00AM	Journal of Clinical Psychiatry Publishes Data from Alkermes' ALPINE Study in Patients With Schizophrenia PR Newswire
May-14-20 07:00AM	Alkermes Presents New Data From Schizophrenia Portfolio at Virtual 2020 Congress of the Schizophrenia International Research Society PR Newswire
May-11-20 07:00AM	Alkermes Announces Expansion of Patient Services and Provider Network to Support Uninterrupted Access to ARISTADA® and VIVITROL® During COVID-19 Crisis PR Newswire
May-06-20 04:00PM	Alkermes Announces Upcoming Presentation at the Bank of America Securities Virtual Health Care Conference PR Newswire
May-01-20 09:45AM	Analysts Have Lowered Expectations For Alkermes plc (NASDAQ:ALKS) After Its Latest Results Simply Wall St.
Apr-30-20 11:12AM	Alkermes' (ALKS) Q1 Earnings Increase Y/Y, Revenues Beat Zacks
Apr-29-20 03:00PM	Alkermes PLC (ALKS) Q1 2020 Earnings Call Transcript Motley Fool -10.59%
07:47AM	Alkermes: Q1 Earnings Insights Benzinga

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also ALKS 3831 to treat schizophrenia; and ALKS 4230, an engineered fusion protein to expand tumor-killing immune cells and to avoid activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DIXON WENDY L	Director	Jan 13	Option Exercise	12.62	35,000	441,700	36,600	Jan 15 04:38 PM
MITCHELL PAUL J	Director	Oct 01	Option Exercise	14.92	20,000	298,400	27,000	Oct 02 04:40 PM
MITCHELL PAUL J	Director	Oct 01	Sale	16.61	20,000	332,262	7,000	Oct 02 04:40 PM
ANSTICE DAVID W	Director	Sep 28	Option Exercise	14.92	20,000	298,400	86,213	Oct 05 05:46 PM
ANSTICE DAVID W	Director	Sep 28	Sale	16.79	17,832	299,310	68,381	Oct 05 05:46 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	Jul 14	Option Exercise	18.11	5,523	99,994	207,345	Jul 15 04:55 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jun 07	Option Exercise	0.00	1,250	0	15,201	Jun 08 04:21 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	Jun 05	Option Exercise	0.00	3,500	0	3,500	Jun 08 04:19 PM
POPS RICHARD F	Director and CEO, Alkermes plc	May 14	Option Exercise	11.74	75,000	880,500	834,094	May 14 05:00 PM
FRATES JAMES M	SVP, Alks Inc; CFO ALKS	May 14	Option Exercise	11.74	21,983	258,080	91,828	May 14 04:58 PM
POPS RICHARD F	Director and CEO, Alkermes plc	May 14	Sale	15.00	75,000	1,125,233	759,094	May 14 05:00 PM
Brown Iain Michael	SVP Finance & CAO, Alks Inc.	May 13	Option Exercise	11.74	6,250	73,375	44,831	May 14 04:55 PM
Brown Iain Michael	SVP Finance & CAO, Alks Inc.	May 13	Sale	15.39	6,250	96,193	38,581	May 14 04:55 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	May 12	Option Exercise	11.74	18,000	211,320	219,822	May 14 04:54 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	May 12	Sale	15.75	18,000	283,469	201,822	May 14 04:54 PM
POPS RICHARD F	Director and CEO, Alkermes plc	May 07	Option Exercise	11.74	50,000	587,000	809,094	May 07 04:26 PM
POPS RICHARD F	Director and CEO, Alkermes plc	May 07	Sale	14.63	50,000	731,265	759,094	May 07 04:26 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	May 05	Option Exercise	11.74	25,000	293,500	226,822	May 07 04:25 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	May 05	Sale	14.06	25,000	351,425	201,822	May 07 04:25 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Apr 02	Option Exercise	11.74	50,000	587,000	809,094	Apr 03 04:22 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Apr 02	Sale	13.79	50,000	689,500	759,094	Apr 03 04:22 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Mar 26	Option Exercise	11.74	75,000	880,500	834,094	Mar 26 04:38 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Mar 26	Sale	14.36	75,000	1,077,225	759,094	Mar 26 04:38 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	Mar 24	Option Exercise	11.74	25,000	293,500	226,822	Mar 26 04:36 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	Mar 24	Sale	13.91	25,000	347,718	201,822	Mar 26 04:36 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Mar 19	Option Exercise	11.74	75,000	880,500	834,094	Mar 19 04:10 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Mar 19	Sale	14.47	75,000	1,085,428	759,094	Mar 19 04:10 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	Mar 17	Option Exercise	11.74	25,000	293,500	226,822	Mar 19 04:10 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	Mar 17	Sale	13.54	25,000	338,506	201,822	Mar 19 04:10 PM
Gaffin David Joseph	SVP, CLO, Alkermes, Inc.	Mar 02	Option Exercise	11.74	3,000	35,220	61,934	Mar 03 04:31 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Mar 01	Option Exercise	0.00	17,500	0	766,864	Mar 03 04:36 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	Mar 01	Option Exercise	0.00	4,500	0	201,822	Mar 03 04:33 PM
Gaffin David Joseph	SVP, CLO, Alkermes, Inc.	Mar 01	Option Exercise	0.00	2,250	0	59,596	Mar 03 04:31 PM
FRATES JAMES M	SVP, Alks Inc; CFO ALKS	Mar 01	Option Exercise	0.00	4,500	0	71,168	Mar 03 04:27 PM
Brown Iain Michael	SVP Finance & CAO, Alks Inc.	Mar 01	Option Exercise	0.00	2,250	0	39,243	Mar 03 04:23 PM
Wysenski Nancy	Director	Feb 24	Buy	19.65	6,940	136,371	11,242	Feb 25 05:15 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Feb 21	Option Exercise	0.00	32,400	0	763,750	Feb 24 04:15 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	Feb 21	Option Exercise	0.00	5,825	0	197,322	Feb 24 04:14 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 21	Option Exercise	0.00	6,875	0	15,955	Feb 24 04:13 PM
Gaffin David Joseph	SVP, CLO, Alkermes, Inc.	Feb 21	Option Exercise	0.00	6,875	0	59,362	Feb 24 04:12 PM
FRATES JAMES M	SVP, Alks Inc; CFO ALKS	Feb 21	Option Exercise	0.00	5,825	0	68,380	Feb 24 04:11 PM
Brown Iain Michael	SVP Finance & CAO, Alks Inc.	Feb 21	Option Exercise	0.00	4,800	0	38,384	Feb 24 04:10 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Feb 17	Option Exercise	0.00	8,750	0	735,236	Feb 18 04:12 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	Feb 17	Option Exercise	0.00	3,000	0	191,497	Feb 18 04:11 PM
Gaffin David Joseph	SVP, CLO, Alkermes, Inc.	Feb 17	Option Exercise	0.00	2,500	0	53,253	Feb 18 04:09 PM
FRATES JAMES M	SVP, Alks Inc; CFO ALKS	Feb 17	Option Exercise	0.00	3,000	0	63,459	Feb 18 04:07 PM
Brown Iain Michael	SVP Finance & CAO, Alks Inc.	Feb 17	Option Exercise	0.00	2,500	0	34,452	Feb 18 04:05 PM
POPS RICHARD F	Director and CEO, Alkermes plc	Feb 16	Option Exercise	0.00	18,125	0	734,558	Feb 18 04:12 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 16	Option Exercise	0.00	3,375	0	10,252	Feb 18 04:10 PM
LANDINE MICHAEL J	SVP, Corp Dev., Alkermes, Inc.	Feb 16	Option Exercise	0.00	3,375	0	188,497	Feb 18 04:11 PM
Gaffin David Joseph	SVP, CLO, Alkermes, Inc.	Feb 16	Option Exercise	0.00	3,375	0	51,925	Feb 18 04:09 PM
FRATES JAMES M	SVP, Alks Inc; CFO ALKS	Feb 16	Option Exercise	0.00	3,375	0	61,631	Feb 18 04:07 PM
Brown Iain Michael	SVP Finance & CAO, Alks Inc.	Feb 16	Option Exercise	0.00	2,375	0	32,777	Feb 18 04:05 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience